CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Deferred Compensation Arrangement with Individual, Compensation Expense
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Deferred Compensation Arrangement with Individual, Compensation Expense of $3.40 million for the 12-month period ending 2025-12-27, per its 10-K filed 2026-02-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense · last filed 2026-02-18
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. deferred compensation arrangement with individual, compensation expense for fiscal 2025 was $3.40M, a 13.33% increase from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. deferred compensation arrangement with individual, compensation expense for fiscal 2024 was $3.00M, a 7.14% increase from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. deferred compensation arrangement with individual, compensation expense for fiscal 2023 was $2.80M, a 34.88% decline from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. deferred compensation arrangement with individual, compensation expense for fiscal 2022 was $4.30M, a 0.00% change from fiscal 2021.
| Period end | Deferred Compensation Arrangement with Individual, Compensation Expense 12 month |
|---|---|
| 2025-12-27 | $3.40M 10-K · filed 2026-02-18 |
| 2024-12-28 | $3.00M 10-K · filed 2026-02-18 |
| 2023-12-30 | $2.80M 10-K · filed 2026-02-18 |
| 2022-12-31 | $4.30M 10-K · filed 2025-02-19 |
| 2021-12-25 | $4.30M 10-K · filed 2024-02-14 |
| 2020-12-26 | $5.70M 10-K · filed 2023-02-22 |
| 2019-12-28 | $2.50M 10-K · filed 2022-02-16 |
| 2018-12-29 | $2.90M 10-K · filed 2021-02-17 |
| 2017-12-30 | $2.30M 10-K · filed 2020-02-11 |
| 2016-12-31 | $2.20M 10-K · filed 2019-02-13 |
| 2015-12-26 | $2.60M 10-K · filed 2018-02-13 |
| 2014-12-27 | $3.30M 10-K · filed 2017-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |